NYC Attorneys Representing Patients Injured By Belviq
Pharmaceutical companies have long tried to develop weight loss drugs that are both safe and effective. Unfortunately, nearly all of these drugs have proven to be dangerous to patient health, and many have become the subject of litigation after being removed from the market.
The latest drug to join this trend is Belviq (lorcaserin), manufactured by a Japanese company called Eisai Inc. Belviq was first approved in 2012 but was pulled from the market in early 2020, along with Belviq XR (the extended-release version).
Study Showed Elevated Cancer Risk
The Food and Drug Administration asked pharmaceutical manufacturer Eisai Inc. to conduct a five-year study of 12,000 patients as condition of approval. While the study was intended to assess the risk of heart problems (which were not found), the results revealed that users of Belviq had cancer rates of 7.7 percent, compared to 7.1 percent in the control group.
The most commonly reported forms of cancer included:
- Pancreatic cancer
- Colorectal cancer
- Lung cancer
As a result of the findings, the FDA asked the drug manufacturer to remove it from the U.S. market and issued a recall. The agency instructed patients taking Belviq to immediately stop using the drug and to safely dispose of any leftover pills.
Have You Been Harmed By Belviq Or Any Other Dangerous Drug?
If you’ve developed cancer and believe it may be tied to your use of the drug Belviq or Belviq XR, you may able to hold the drug manufacturer legally and financially liable. The attorneys at , are proud to represent consumers who have been harmed by dangerous drugs, and we will fight to help you claim the compensation you need and deserve.
Contact a Product Liability Lawyer in New York For A Free Initial Consultation
From our offices on Wall Street, our firm serves clients throughout the New York City area. To discuss your case with a caring and experienced personal injury attorney, call us at 212-514-5007 or 800-724-7971. You can also fill out our online contact form.